Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer (Q37395384)

20 August 2017

Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer (English)

1 reference

20 August 2017

phase III clinical trial

0 references

1 reference

1 reference

Randall E Millikan

1

1 reference

20 August 2017

Sijin Wen

2

1 reference

20 August 2017

Lance C Pagliaro

3

1 reference

20 August 2017

Melissa A Brown

4

1 reference

20 August 2017

Brenda Moomey

5

1 reference

20 August 2017

Kim-Anh Do

6

1 reference

20 August 2017

Christopher J Logothetis

7

1 reference

20 August 2017

language of work or name

English

0 references

publication date

24 November 2008

1 reference

Journal of Clinical Oncology

20 August 2017

1 reference

20 August 2017

26

1 reference

20 August 2017

36

1 reference

20 August 2017

5936-5942

1 reference

Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

6 September 2017

Cancer statistics, 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Chemotherapy for hormone-refractory prostate cancer: beauty is in the eye of the beholder

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864402

Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer

2 September 2018

1 reference

12 December 2020

Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial

1 reference

12 December 2020

Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial

1 reference

12 December 2020

Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure

1 reference

12 December 2020

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

1 reference

12 December 2020

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

1 reference

12 December 2020

Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer

1 reference

12 December 2020

Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2007.15.9830

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

19029421

1 reference